For Immediate Release
Chicago, IL – March 12, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amazon.com, Inc. (AMZN - Free Report) , IBM Corp. (IBM - Free Report) , Biogen Inc. (BIIB - Free Report) , Newmont Corp. (NEM - Free Report) and Berkshire Hathaway Inc. (BRK.B - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Amazon, IBM and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., IBM Corp. and Biogen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Amazon’s shares have outperformed the Zacks Internet - Commerce industry so far this year (+2.4% vs. -1.3%). Amazon reported impressive fourth-quarter results wherein both earnings and revenues topped the estimates and grew on a year-over-year basis.
The company benefited from solid Prime momentum owing to ultrafast delivery services and expanding original content portfolio. Moreover, it witnessed strong growth in the Prime paid membership. Further, strengthening AWS services and its growing adoption rate contributed well.
However, rising transportation cost related to its free one-day shipping service remains an overhang. Further, foreign exchange headwinds are concerns. Also, rising cloud competition from Microsoft and Google poses risk.
(You can read the full research report on Amazon here >>>)
IBM’s shares have declined 9.8% over the past one-year period against the Zacks Computer - Integrated Systems industry’s fall of 11.2%. But things are looking up for IBM after it reported stellar Q4 results. Moreover, the company provided promising bottom-line guidance for 2020. IBM’s improving position in the hosted cloud, security and analytics aided revenue performance.
The RedHat acquisition has helped IBM to enhance containerized software capabilities. Robust adoption of security solutions, including Resilient and QRadar, bodes well.
Further, gains from z15 and high demand for data privacy and resiliency solutions across hybrid cloud are positives. Also, IBM’s time-consuming business model transition to cloud is a headwind.
(You can read the full research report on IBM here >>>)
Biogen’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry on a year-to-date basis (+3.0% vs. -5.7%). Biogen’s efforts to diversify beyond MS to other areas are commendable. Spinraza has multi-billion-dollar potential. Biogen regularly in-licenses assets to build its pipeline.
Several important data readouts are expected in 2020-2021. Its intention to seek U.S. approval of Alzheimer’s treatment, aducanumab, a few months after it halted late-stage studies on the same drug following a futility analysis, gave a major boost to the stock.
However, competitive pressure is expected to rise in 2020 in MS market. And even though Biogen’s CNS pipeline is attractive, it is a high-risk area.
(You can read the full research report on Biogen here >>>)
Other noteworthy reports we are featuring today include Newmont Corp. and Berkshire Hathaway Inc.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.